适当的治疗顺序对结抵抗性前列腺癌的治疗
Neal D Shore1, Michael S Cookson2
1Carolina Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina.
Urology practice
|August 3, 2023
概括
自2010年以来,转移性割抵抗性前列腺癌的治疗已取得显著进展,有5种新的FDA批准的疗法. 本综述指导临床医生对这些新型治疗方法进行测序,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
背景情况:
- 雄激素剥夺疗法 (ADT) 最初会诱导前列腺癌的缓解,但疾病进展到割抵抗是不可避免的.
- 转移性割抵抗性前列腺癌 (mCRPC) 是一个重大的临床挑战.
- 最近的进展极大地扩大了mCRPC的治疗选择.
研究的目的:
- 审查目前mCRPC治疗选择的情况.
- 提供关于新型mCRPC疗法测序的指导.
- 帮助临床医生管理晚期前列腺癌.
主要方法:
- 对mCRPC治疗发表的同行评审文献的审查.
- 对FDA批准的治疗割抵抗性前列腺癌的药物的分析.
- 检查支持新疗法的临床试验数据.
主要成果:
- 五种新的药物 (sipuleucel-T,cabazitaxel,abiraterone,enzalutamide,二) 已获得FDA对mCRPC的批准.
- 这些疗法提供了经过验证的生存益处.
- 美国泌尿器官学会 (AUA) 在2013年制定了指导方针,以帮助临床医生.
结论:
- 针对mCRPC的多种新疗法已得到快速批准.
- 了解独特的行动和交付机制至关重要.
- 测序这些疗法需要文献审查,临床判断和经验.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K